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Background:  Clopidogrel’s active metabolite inhibits platelet activation via the P2Y12 ADP receptor and reduces ischemic events in patients with 
acute coronary syndromes. Metabolism of clopidogrel requires cytochrome P450s, including CYP2C19. However, proton pump inhibitors (PPIs) may 
inhibit CYP2C19, potentially reducing clopidogrel’s effectiveness. Because PPIs differ in their degree of inhibition of CYP2C19, we rigorously evaluated 
the effect of dexlansoprazole (DPZ), lansoprazole (LPZ), esomeprazole (EPZ) and omeprazole (OPZ) on clopidogrel’s steady-state pharmacokinetics 
(PK) and pharmacodynamics (PD).
Methods:  Healthy subjects (n=160 [40/PPI], age 18-55, homozygous CYP2C19 extensive metabolizer genotype, confined, standardized diet) were 
randomized to a PPI and then to a sequence of clopidogrel alone followed by a washout then clopidogrel + PPI, or clopidogrel + PPI followed by a 
washout then clopidogrel alone. Clopidogrel 75 mg with or without a PPI (DPZ 60 mg, LPZ 30 mg, EPZ 40 mg or, as a positive control to maximize 
potential interaction and demonstrate assay sensitivity, OPZ 80 mg) was given daily for 9 days. PK and PD were collected on day 9/10 of each 
period. PD end points were VASP P2Y12 platelet reactivity index (PRI), maximal platelet aggregation (MPA) to 5 and 20 μM ADP, and VerifyNow P2Y12 
platelet response units (PRU).
Results:  PK and PD responses with OPZ demonstrated assay sensitivity. The area under the curve for clopidogrel active metabolite decreased 
significantly with EPZ or OPZ but not with DPZ or LPZ. Similarly, EPZ or OPZ but not DPZ or LPZ significantly reduced clopidogrel’s effect on VASP PRI. 
All PPIs decreased (DPZ&LPZ<EPZ&OPZ) clopidogrel active metabolite peak plasma concentration and showed a corresponding order of potency for 
effects on MPA and PRU.
Conclusions:  In this randomized, open-label, 2-period, crossover study, generation of clopidogrel’s active metabolite and inhibition of platelet 
function were reduced less by co-administration of DPZ or LPZ with clopidogrel than by co-administration of EPZ. These results suggest that potential 
effects of PPIs on clopidogrel’s activity could be minimized by use of DPZ or LPZ rather than EPZ.
